(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 November 2012 (08.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/151248 A2

(51) International Patent Classification:
A61P 1/00 (2006.01)

(21) International Application Number:
PCT/US2012/036072

(22) International Filing Date:
2 May 2012 (02.05.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/481,533	2 May 2011 (02.05.2011)	US
61/550,545	24 October 2011 (24.10.2011)	US
61/585,859	12 January 2012 (12.01.2012)	US

(71) Applicant *(for all designated States except US)*: **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DILUZIO, Willow** [US/US]; 7 Fernwood Drive, Westford, Massachusetts 01886 (US). **TRUONG, Nobel T.** [US/US]; 26 Stailbrook Road, Milford, Massachusetts 01757 (US). **VARGA, Csanad M.** [US/US]; 95 Jackson Street, Cambridge, Massachusetts 02140 (US). **PALANIAPPAN, Vaithianathan** [US/US]; 7 Spruce Circle, Andover, Massachusetts 01810 (US). **BROWN, Jason** [US/US]; 10 September Lane, Burlington, Massachusetts 01803 (US). **FOX, Irving H.** [US/US]; 111 Livingston Road, Wellesley, Massachusetts 02482 (US). **SCHOLZ, Catherine** [US/US]; 1 Nashua Street, Woburn, Massachusetts 01801 (US).

(74) Agents: **UNDERWOOD, Robert H.** et al.; McDermott Will & Emery LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/151248 A2

(54) Title: FORMULATION FOR ANTI-α4β7 ANTIBODY

(57) Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.